27 November 2020
Latham Advises ATAI Life Sciences on US$125 Million Series C
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Robbie McLaren Lead | Latham & Watkins LLP | Partner | corporate | London |
| Markus Krueger Lead | Latham & Watkins LLP | Partner | corporate | Frankfurt |
| Jon Fox | Latham & Watkins LLP | Associate | Not stated | Not stated |
| David Funken | Latham & Watkins LLP | Associate | Not stated | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 125m (US$125 million)
- What the figure measures
- Issue size
- Client
- ATAI Life SciencesIssuer
- Counterparties
- Apeiron Investment Group (Investor)
Peter Thiel (Investor)
Catalio Capital Management (Investor)